Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database

被引:6
作者
Hirata, Aya [1 ,2 ]
Hirata, Takumi [3 ]
Takahashi, Yoshimitsu [2 ]
Nakayama, Takeo [2 ]
机构
[1] Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Tokyo 1608582, Japan
[2] Kyoto Univ, Sch Publ Hlth, Dept Hlth Informat, Kyoto 6068501, Japan
[3] Keio Univ, Ctr Supercentenarian Med Res, Sch Med, Tokyo 108, Japan
关键词
hepatocellular carcinoma; Japan; medical claims data; practice guidelines; surveillance; VIRUS; INVOLVEMENT; MANAGEMENT; ETIOLOGY; VETERANS; RISK; CARE;
D O I
10.1111/hepr.12714
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AimSurveillance is recommended for patients with risk of hepatocellular carcinoma (HCC) such as viral hepatitis and liver cirrhosis (LC). Although populations are at higher risk in Asia, surveillance rates have not been evaluated in those countries. Therefore, we aimed to examine surveillance rates for HCC and to compare predictors for surveillance among each type of liver disease in Japan. MethodsWe carried out an observational study using the medical claims data of Japan. A total of 4713 patients who were diagnosed with LC, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection were followed for 12months. We described surveillance rates in patients with HBV or HCV infection or non-viral LC and evaluated potential predictors for follow-up surveillance among them by using multivariable logistic regression analysis, in which we set explanatory variables as sex, age, medical facility, HBV or HCV infection, and LC. ResultsThe HCC surveillance rate during follow-up was 42.3% among patients with chronic viral hepatitis, 56.5% with viral cirrhosis and 26.0%, with non-viral LC. Significant predictors for follow-up surveillance were presence of LC and hospital visits. Hepatitis B virus-infected patients aged <50years and HCV-infected patients aged 50years were more likely to undergo exams, that is, different tendencies between HBV and HCV patients were shown. ConclusionsFollow-up surveillance for HCC was not adequately carried out among patients at risk for HCC in Japan, despite of recommendation in guidelines. In future, methodological research might be needed to increase surveillance rates for HCC in patients with chronic hepatitis or those who received treatment at a clinic.
引用
收藏
页码:283 / 292
页数:10
相关论文
共 32 条
[1]  
[Anonymous], GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012
[2]  
[Anonymous], 2005, CLIN PRACT GUID HEP
[3]  
[Anonymous], 2019, CLIN PRACTICE GUIDEL
[4]  
BEASLEY RP, 1981, LANCET, V2, P1129
[5]   Socioeconomic and Sociodemographic Predictors of Cancer-Related Information Sources Used by Cancer Survivors [J].
Blanch-Hartigan, Danielle ;
Viswanath, Kasisomayajula .
JOURNAL OF HEALTH COMMUNICATION, 2015, 20 (02) :204-210
[6]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[7]   Utilization of screening for hepatocellular carcinoma in the United States [J].
Davila, Jessica A. ;
Weston, Allan ;
Smalley, Walter ;
El-Serag, Hashem B. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (08) :777-782
[8]   Utilization of Surveillance for Hepatocellular Carcinoma Among Hepatitis C Virus-Infected Veterans in the United States [J].
Davila, Jessica A. ;
Henderson, Louise ;
Kramer, Jennifer R. ;
Kanwal, Fasiha ;
Richardson, Peter A. ;
Duan, Zhigang ;
El-Serag, Hashem B. .
ANNALS OF INTERNAL MEDICINE, 2011, 154 (02) :85-+
[9]   Use of Surveillance for Hepatocellular Carcinoma Among Patients With Cirrhosis in the United States [J].
Davila, Jessica A. ;
Morgan, Robert O. ;
Richardson, Peter A. ;
Du, Xianglin L. ;
McGlynn, Katherine A. ;
El-Serag, Hashem B. .
HEPATOLOGY, 2010, 52 (01) :132-141
[10]   Surveillance for Hepatocellular Carcinoma [J].
Della Corte, Cristina ;
Colombo, Massimo .
SEMINARS IN ONCOLOGY, 2012, 39 (04) :384-398